Neal S. Akhave

Neal S. Akhave

Auto-generated profile, based on publicly available information

Neal S. Akhave

The University of Texas MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MNMarcelo V. Negrao
Marcelo V. Negrao
HAHaniel A. Araujo
Haniel A. Araujo
GLGiuseppe Lamberti
Giuseppe Lamberti
ACAlissa J. Cooper
Alissa J. Cooper
NANeal S. Akhave
Neal S. Akhave
FSFerdinandos Skoulidis
Ferdinandos Skoulidis
Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRASG12C-mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis of 424 patients with non–small cell lung cancer (NSCLC), we identified and validated coalterations in KEAP1, SMARCA4, and CDKN2A as major independent determinants of inferior clinical outcomes with KRASG12Ci monotherapy. Collectively, comutations in these three tumor suppressor genes segregated patients into distinct prognostic subgroups and captured ∼50% of those with early disease progression (progression-free survival ≤3 months) with KRASG12Ci. Pathway-level integration of less prevalent coalterations in functionally related genes nominated PI3K/AKT/MTOR pathway and additional baseline RAS gene alterations, including amplifications, as candidate drivers of inferior outcomes with KRASG12Ci, and revealed a possible association between defective DNA damage response/repair and improved KRASG12Ci efficacy. Our findings propose a framework for patient stratification and clinical outcome prediction in KRASG12C-mutant NSCLC that can inform rational selection and appropriate tailoring of emerging combination therapies. Significance: In this work, we identify co-occurring genomic alterations in KEAP1, SMARCA4, and CDKN2A as independent determinants of poor clinical outcomes with KRASG12Ci monotherapy in advanced NSCLC, and we propose a framework for patient stratification and treatment personalization based on the comutational status of individual tumors. See related commentary by Heng et al., p. 1513. This article is highlighted in the In This Issue feature, p. 1501

10 August 2022 in Lung Cancer
Verified
Journal Article
Closed access
NANeal Akhave
Neal Akhave
JZJiexin Zhang
Jiexin Zhang
EBErin Bayley
Erin Bayley
MFMeredith Frank
Meredith Frank
SCShin-Heng Chiou
Shin-Heng Chiou
Alexandre ReubenAlexandre Reuben
Alexandre Reuben

24 October 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
NANeal S. Akhave
Neal S. Akhave
ABAmadeo B. Biter
Amadeo B. Biter
DHDavid S. Hong
David S. Hong
The development of selective KRASG12C inhibitors that directly inhibit KRAS, an oncogene historically thought to be “undruggable,” represents a watershed moment in oncology and developmental therapeutics. Now, as KRAS-targeted therapy moves into its second phase, there is significant excitement and anticipation for durable disease control in tumor types where options remain limited, with clinical trials testing combination therapies, indirect pan-RAS/MAP kinase pathway inhibitors, and active-state RAS(on) inhibitors. However, there is also reason for caution regarding the safety and tolerability of expanded RAS inhibition. This is evidenced by the intolerability of some combination therapies with selective KRASG12C inhibitors and foreshadowed by prior failures of combination therapies in other oncogene-driven tumors. Herein, we review the landscape of and outlook for KRAS-targeted therapies. We specifically focus upon strategies to combat resistance to KRAS-targeted therapies, and discuss the possibility of off-target or unanticipated on-target effects that may limit clinical use.

20 July 2024 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
BEBita Esmaeli
Bita Esmaeli
JFJanet Fan
Janet Fan
HGHila Goldberg
Hila Goldberg
TLTracy Lu
Tracy Lu
NGNeil D. Gross
Neil D. Gross
RFRenata Ferrarotto
Renata Ferrarotto

31 August 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
LSLauren K. Shea
Lauren K. Shea
NANeal S. Akhave
Neal S. Akhave
LSLeslie A. Sutton
Leslie A. Sutton
LCLeigh A. Compton
Leigh A. Compton
CYConner York
Conner York
DCDavid Y. Chen
David Y. Chen

10 May 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Nabil SabaNabil Saba
Nabil Saba
NINofisat Ismaila
Nofisat Ismaila
DADouglas Adkins
Douglas Adkins
NANishant Agrawal
Nishant Agrawal
NANeil Akhave
Neil Akhave
BBBeth M. Beadle
Beth M. Beadle
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE: To provide evidence-based recommendations on the use of systemic therapy in different types of thyroid cancers. METHODS: The American Society of Clinical Oncology convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. The literature search included studies published between January 1, 2000, and November 5, 2025, and comprised systematic reviews, meta-analyses, randomized controlled trials, and observational studies. Outcomes of interest included overall survival, disease-free survival, and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: A total of 66 publications were identified to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations address the use of systemic therapy in patients with well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer. Additional information is available at https://ascopubs.org/topics/asco-guidelines/head-neck-cancer .